Fluorocycline TP-271 is potent against complicated community-acquired bacterial pneumonia pathogens

mSphere

Volumn 2, Issue 1, 2017, Pages

  Grossman, Trudy H ^a,h   Fyfe, Corey ^a   O'Brien, William ^a,h   Hackel, Meredith ^b   Minyard, Mary Beth ^c,i   Waites, Ken B ^d   Dubois, Jacques ^e   Murphy, Timothy M ^f,j   Slee, Andrew M ^f,k   Weiss, William J ^g   Sutcliffe, Joyce A ^a,l  

^a Tetraphase Pharmaceuticals Inc   (United States)

^b International Health Management Associates   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e M360   (Canada)

^f ViviSource Laboratories   (United States)

^g UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^h MBMicrobio Consulting ^*  (United States)

ⁱ MBMicrobio Consulting   (United States)

^j NeoSome Life Sciences   (United States)

^k NONE   (United States)

^l NONE   (United States)

more..

Author keywords

Community acquired bacterial pneumonia; Fluorocycline; TP 271

Indexed keywords

EID: 85031426219     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00004-17     Document Type: Article

References (39)

1. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr, Musher DM, Whitney C; Infectious Diseases Society of America. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405-1433. https://doi.org/10 .1086/380488
2. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. 1996. Prognosis and outcomes of patients with communityacquired pneumonia. A meta-analysis. JAMA 275:134-141. https://doi .org/10.1001/jama.275.2.134
3. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. 2002. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 166:717-723. https://doi.org/10.1164/rccm.2102084
4. GBD 2013 Mortality and Causes of Death Collaborators. 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117-171. https://doi .org/10.1016/S0140-6736(14)61682-2
5. CDC. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA
6. File TM. 2009. The science of selecting antimicrobials for communityacquired pneumonia (CAP). J Manag Care Pharm 15:S5-S11. https://doi .org/10.18553/jmcp.2009.15.s2.5
7. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 44:S27-S72. https://doi .org/10.1086/511159
8. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. 2005. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854-3862. https://doi.org/10.1378/chest.128.6.3854
9. Wunderink RG. 2013. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy? Infect Dis Clin North Am 27:177-188. https:// doi.org/10.1016/j.idc.2012.11.006
10. Rubinstein E, Kollef MH, Nathwani D. 2008. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46:S378-S385. https://doi.org/10.1086/533594
11. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J. 2003. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 9:978-984. https://doi.org/10.3201/eid0908.030089
12. Boyle-Vavra S, Daum RS. 2007. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87:3-9. https://doi.org/10.1038/labinvest.3700501
13. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. 2011. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 52:99-114. https://doi.org/10.1093/cid/ciq067
14. Dalhoff A. 2012. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012:976273. https://doi.org/10.1155/2012/976273
15. Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ. 2015. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013. Ann Clin Microbiol Antimicrob 14:27. https://doi.org/10.1186/s12941-015-0085-1
16. Pfaller MA, Farrell DJ, Sader HS, Jones RN. 2012. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 55(Suppl 3):S187-S193. https://doi.org/10.1093/cid/cis561
17. Nicolau D. 2002. Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J Antimicrob Chemother 50:61-70. https://doi.org/10.1093/ jac/dkf809
18. Waites KB, Lysynyansky I, Bébéar CM. 2014. Antibiotic susceptibility testing and resistance in mycoplasmas of humans and animals. In Browning G, Citti C (ed), Mollicutes: molecular biology and pathogenesis. Caister Academic Press, United Kingdom
19. Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, Hong T, Todd K, Ratliff AE, Crabb DM, Xiao L, Atkinson TP, Waites KB. 2015. Macrolideresistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 21: 1470-1472. https://doi.org/10.3201/eid2108.150273
20. Brodersen DE, Clemons WM, Jr, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. 2000. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103:1143-1154. https://doi.org/10.1016/S0092-8674 (00)00216-6
21. Pioletti M, Schlünzen F, Harms J, Zarivach R, Glühmann M, Avila H, Bashan A, Bartels H, Auerbach T, Jacobi C, Hartsch T, Yonath A, Franceschi F. 2001. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J 20:1829-1839. https:// doi.org/10.1093/emboj/20.8.1829
22. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559-2564. https://doi.org/10.1128/AAC.06187-11
23. FDA. 2016. Guidance for industry: microbiological data for systemic antibacterial drug products-development, analysis, and presentation. Guidance August 2016; US Department of Health and Human Services. FDA CDER. FDA, Silver Spring, MD
24. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149-2152. https://doi.org/10.1086/430352
25. Dubois J, Dubois M, Martel J, Grossman T, Sutcliffe J. 2010. In vitro activity of fluorocyclines against Legionella pneumophila. In Abstr 50th Intersci Conf Antimicrob Agents Chemother, Boston, MA, abstr F 1-2159
26. Roberts MC. 2005. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 245:195-203. https://doi.org/10.1016/j.femsle.2005 .02.034
27. Speer BS, Bedzyk L, Salyers AA. 1991. Evidence that a novel tetracycline resistance gene found on two Bacteroides transposons encodes an NADP-requiring oxidoreductase. J Bacteriol 173:176-183. https://doi .org/10.1128/jb.173.1.176-183.1991
28. Yang W, Moore IF, Koteva KP, Bareich DC, Hughes DW, Wright GD. 2004. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 279:52346-52352. https://doi.org/ 10.1074/jbc.M409573200
29. Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 172: 6942-6949. https://doi.org/10.1128/jb.172.12.6942-6949.1990
30. Kaatz GW, Seo SM, Ruble CA. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 37: 1086-1094. https://doi.org/10.1128/AAC.37.5.1086
31. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49:1865-1871. https://doi.org/10.1128/AAC.49.5.1865-1871.2005
32. Kaatz GW, Moudgal VV, Seo SM. 2002. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother 50:833-838. https://doi.org/10.1093 /jac/dkf224
33. Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA. 2012. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597-605. https://doi.org/10.1021/jm201465w
34. CLSI. 2015. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10, vol 32, no 2. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania
35. CLSI. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document m100-S25, vol 35 Clinical and Laboratory Standards Institute, Wayne, PA
36. Edelstein PH. 2007. Legionella, p 835-849. In Murray P, Baron E, Jorgensen JH, Landry ML, Pfaller MA (ed), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC
37. CLSI. 2011. Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline. CLSI document M43-A, vol 31, no 19. Clinical and Laboratory Standards Institute, Wayne, PA
38. Campbell LA, Kuo CC. 2009. Cultivation and laboratory maintenance of Chlamydia pneumoniae. Curr Protoc Microbiol 11:B:11B.1:11B.1.1-11B.1.2. https://doi.org/10.1002/9780471729259.mc11b01s12
39. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548-5558. https://doi.org/10.1128/AAC.01288-13